Avance Clinical, a partner for biotechs providing global contract research organization services, has now guided 710 emerging biotechs through critical clinical trial inflection points.

Avance Clinical’s comprehensive approach to Phase I clinical development has delivered consistent results across the portfolio, bridging studies and first-in-human trials. Most of these programs have successfully advanced to their next milestone, including securing follow-on funding, progressing to Phase II trials, and initiating more pivotal studies.

“Too often biotechs stall, not because of science, but because they are unable to navigate early-phase inflection points efficiently,” said Mark Harvill, CEO, at Avance Clinical. “Much like a start-up benefits from a solid foundation, we’re creating the acceleration for emerging biotechs to help them get to those critical milestones. By accelerating timelines by as much as nine months, we’re advancing their progress and potentially delivering life-changing treatments to patients sooner.”

Those common hurdles which stall early-stage biotechs are largely due to strategic or operational misalignment. Most often, biotechs experience this in:

• Delayed toxicology data, which can postpone regulatory submission
• Funding gaps, which slow the start of a study or progression to the next phase
• Internal hiring delays, which can leave a client under resourced during critical phases
• Lack of strategic planning, which allows teams to anticipate potential bottlenecks before they occur

Avance Clinical addresses these challenges proactively by assessing early data and preparing regulatory submissions up front. This approach ensures clients can anticipate roadblocks, reduce delays, protect capital from the beginning, and overall provide greater confidence to reach their next inflection point.

“These achievements highlight the strategic value of integrating operational excellence with expert regulatory guidance to de-risk early-stage development,” said Ben Edwards, Chief Operating Officer, at Avance Clinical. “This direction allows us to be the accelerator for our clients to ensure a sustained competitive advantage and progression through later stage development.”

About Avance Clinical

Avance Clinical is the largest premium full-service Australian headquartered CRO delivering high-quality clinical trials in Australia, New Zealand, Asia, North America, and Europe for international biotechs. The company has won multiple Frost & Sullivan CRO Market Leadership and Customer Value Leadership Awards. With over 30 years of experience and deep expertise across more than 250 indications, Avance Clinical provides services from pre-clinical to late-phase trials, supported by best-in-class regulatory, clinical, and operational expertise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250827955668/en/

“Much like a start-up benefits from an accelerator environment, we’re building the launchpad for emerging biotechs,” said Mark Harvill, CEO, of Avance Clinical.